Wanted pages

From Glioblastoma Treatments
Jump to navigationJump to search

List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.

Showing below up to 50 results in range #201 to #250.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Hypercalcemia at high doses of calcitriol; other forms generally safe‏‎ (1 link)
  2. Hypertension, fatigue, hand-foot syndrome, diarrhea, proteinuria, thyroid dysfunction‏‎ (1 link)
  3. Impressive 25.3 months in a study combining vaccine with dose-intense temozolomide.‏‎ (1 link)
  4. Improved progression-free survival in combination with other treatments‏‎ (1 link)
  5. Improvement noted when EGFR inhibitors used in combination treatments, though highly variable‏‎ (1 link)
  6. In a study with newly diagnosed GBM patients, progression-free survival at 6 months was 91% when methadone was added to the standard of care‏‎ (1 link)
  7. In studies, tamoxifen showed potential to improve progression-free survival for GBM patients under specific treatment regimens‏‎ (1 link)
  8. In the glioblastoma study, median overall survival was 9.2 months with low-dose TMZ alone‏‎ (1 link)
  9. In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122‏‎ (1 link)
  10. Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects‏‎ (1 link)
  11. Increased side effects when administered in the morning; however, these are generally manageable with other therapies.‏‎ (1 link)
  12. Initial report on recurrent GBM patients showed a PFS-6 value of 48%‏‎ (1 link)
  13. Initial results indicate a need for dosage optimization to balance efficacy and side effects‏‎ (1 link)
  14. Injection site reactions, fatigue, mild fever, allergic reactions (rare)‏‎ (1 link)
  15. Intracranial edema, nausea, lymph node infection (rare and manageable)‏‎ (1 link)
  16. Investigated primarily in hepatitis and cirrhosis; small studies in cancers such as acute lymphoblastic leukemia, prostate cancer, breast cancer, head and neck cancer, and hepatocellular carcinoma‏‎ (1 link)
  17. Investigational, including early clinical trials‏‎ (1 link)
  18. Less toxicity compared to cisplatin, but may include myelosuppression, nausea, and potential for liver enzyme elevation‏‎ (1 link)
  19. Liver enzyme non-induction, potential increase in chemotherapy concentration, somnolence, constipation, potential liver toxicity‏‎ (1 link)
  20. Localized discomfort, potential damage to surrounding healthy tissue‏‎ (1 link)
  21. Low‏‎ (1 link)
  22. Low blood counts, pulmonary problems, infection, and seizures for Gliadel‏‎ (1 link)
  23. Malnourished advanced cancer patients: 110 days; adequately nourished patients: 350 days; chemotherapy alone in non-small cell lung cancer: 39% one-year survival‏‎ (1 link)
  24. Median DFS of 11.9 months for the vaccine group vs. 5.6 months for the placebo group; HR: 0.52 (95% CI: 0.33-0.82), p = 0.005‏‎ (1 link)
  25. Median OS for glioblastoma patients not taking Keppra: 16.7 months‏‎ (1 link)
  26. Median OS for glioblastoma patients taking Keppra during chemotherapy: 25.7 months‏‎ (1 link)
  27. Median OS not reached for the vaccine group vs. 22.2 months for the placebo group; HR: 0.55 (95% CI: 0.35-0.87), p = 0.011‏‎ (1 link)
  28. Median PFS for patients not taking Keppra: 6.7 months‏‎ (1 link)
  29. Median PFS for patients taking Keppra: 9.4 months‏‎ (1 link)
  30. Median overall survival for GBM is typically 15-17 months from diagnosis‏‎ (1 link)
  31. Median overall survival of 19.3 months from randomization (22.4 months from surgery) for newly diagnosed GBM patients; 13.2 months from relapse for recurrent GBM‏‎ (1 link)
  32. Median overall survival of 20.9 months for newly diagnosed glioblastoma patients when combined with temozolomide, compared to 16.0 months with temozolomide alone‏‎ (1 link)
  33. Median overall survival with standard treatment ranges around 15-17 months for newly diagnosed GBM‏‎ (1 link)
  34. Median progression-free survival of 6.2 months in the DCVax-L arm, compared to 7.6 months in the placebo group, though this difference was not statistically significant‏‎ (1 link)
  35. Median progression-free survival of 6.7 months with TTFields plus temozolomide, versus 4.0 months with temozolomide alone‏‎ (1 link)
  36. Median survival for recurrent GBM typically less than one year‏‎ (1 link)
  37. Median survival of 14.6 months; 2-year survival rate approximately 27%‏‎ (1 link)
  38. Median survival of 42.6 weeks (~9.8 months) in recurrent GBM; Median survival of 23.8 months in newly diagnosed GBM when combined with the Stupp protocol‏‎ (1 link)
  39. Median survival with Tarceva addition: ranges from 15.3 to 19.3 months in studies, though one study showed only 8.6 months‏‎ (1 link)
  40. Median survival with enzyme-inducing anticonvulsants: 11 months‏‎ (1 link)
  41. Median survival with standard Temodar protocol: approximately 14.1 months‏‎ (1 link)
  42. Metformin is under investigation for its potential anti-cancer properties in glioblastoma, particularly its effects on glioma stem cells. Studies focus on its ability to inhibit cell proliferation and induce apoptosis in cancerous cells.‏‎ (1 link)
  43. Mild to moderate skin irritation beneath transducer arrays, thrombocytopenia, nausea, constipation, vomiting, fatigue, headache, convulsions, depression‏‎ (1 link)
  44. Mostly preclinical, involving cell culture studies and some early-stage human research‏‎ (1 link)
  45. Myelosuppression, including neutropenia and lymphopenia; some instances of serious adverse events possibly related to VAL-083‏‎ (1 link)
  46. N/A (Established treatment modality)‏‎ (1 link)
  47. Nausea, constipation (obstipation); side effects commonly resolved after one month of therapy‏‎ (1 link)
  48. Nausea, vomiting, constipation, loss of appetite, fatigue, headache, hair loss, low blood cell counts‏‎ (1 link)
  49. Nausea, vomiting, fatigue, myelosuppression, lymphopenia‏‎ (1 link)
  50. Nephrotoxicity, ototoxicity, and neurotoxicity‏‎ (1 link)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Special:WantedPages"